Form 4: Neurocrine Biosciences Director Exercises Stock Options

Director Johanna Mercier exercised stock options to acquire 2,100 shares of Neurocrine Biosciences common stock on May 17, 2024.

Summary

• On May 17, 2024, Johanna Mercier, a director of Neurocrine Biosciences Inc., exercised stock options.
• This transaction involved the acquisition of 2,100 shares of common stock at a price of $0 per share.
• Following the transaction, Mercier directly owns 2,100 shares of Neurocrine Biosciences common stock.
• The transaction was related to the vesting of Restricted Stock Units (RSUs) granted on May 17, 2023, which are now fully vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a standard transaction (exercise of stock options) by a company director. It doesn't inherently indicate positive or negative performance.

Positives

• The exercise of stock options by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's activity in the company's stock, which is common for executive compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects insider activity, which is generally monitored for insights into management's perspective on the company's value.

Key Dates